Tribonectin polypeptides and uses thereof
AssigneeRhode Island Hospital, A Lifespan-Partner
InventorGregory D. Jay
Life of this patent
Estimating the term…
Abstract
The invention features a lubricating polyeptide and methods of lubricating joints or other tissues by administering the polypeptide systemically or directly to tissues.
Claims25
A lubricating polypeptide comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide, wherein said polypeptide lacks amino acids 26-66 of SEQ ID NO:1.
A lubricating polypeptide comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide, wherein said polypeptide lacks amino acids 107-156 of SEQ ID NO:1.
A lubricating polypeptide comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide, wherein said polypeptide lacks amino acids 157-199 of SEQ ID NO:1.
A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 109-231 of SEQ ID NO:2.
A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 352-501 of SEQ ID NO:2.
A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 502-630 of SEQ ID NO:2.
A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 352-630 of SEQ ID NO:2.
A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 109-231 and 352-630 of SEQ ID NO:2.
A polynucleotide comprising nucleotides 34-501 linked in-frame to nucleotides 631-4245 of SEQ ID NO:2.
A polynucleotide comprising nucleotides 34-501 linked in-frame to nucleotides 631-4245 of SEQ ID NO:2.
A polynucleotide comprising a first sequence comprising nucleotides 34-501 of SEQ ID NO:2, a second sequence comprising nucleotides 232-351 of SEQ ID NO:2, and a third sequence comprising nucleotides 631-4245 of SEQ ID NO:2, wherein said first, second and third sequences are linked in-frame.
A method of reducing a symptom of Camptodactyl-arthropathy-pericarditis syndrome (CAP) in a mammal, comprising administering to said mammal a megakaryocyte stimulating factor polypeptide or an alternatively spliced variant thereof.
The method of claim 19, wherein said polypeptide comprises comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide and wherein said polypeptide lacks amino acids 157-199 of SEQ ID NO:1.
A method of reducing a symptom of CAP in a mammal, comprising administering to said mammal a polynucleotide encoding MSF or an alternatively spliced variant thereof.
A method of reducing a symptom of osteoarthritis in a mammal, comprising administering to said mammal a megakaryocyte stimulating factor polypeptide or an alternatively spliced variant thereof.
A method of reducing a symptom of osteoarthritis in a mammal, comprising administering to said mammal a polynucleotide encoding MSF or an alternatively spliced variant thereof.
Dependencies are inferred from the claim text.